Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.

[1]  W. Scheithauer,et al.  Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer , 2007 .

[2]  L. Collette,et al.  Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases , 2007 .

[3]  B. Nordlinger,et al.  Benefits and risks of neoadjuvant therapy for liver metastases. , 2006, Journal of Clinical Oncology.

[4]  M. Ychou,et al.  Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. , 2006, European journal of cancer.

[5]  Catherine Julié,et al.  Complete response of colorectal liver metastases after chemotherapy: does it mean cure? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Ricci,et al.  First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  P. Morel,et al.  Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary , 2006, The British journal of surgery.

[8]  D. Berger,et al.  RFA for liver tumors: does it really work? , 2006, The oncologist.

[9]  M. Basso,et al.  Long-term follow-up of colorectal cancer (CRC) patients treated with neoadjuvant chemotherapy with irinotecan and fluorouracil plus folinic acid (5-FU/FA) for unresectable liver metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B. Gayet,et al.  Surgery of colorectal metastasis in the Optimox 1 study. A GERCOR Study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  S. Kopetz,et al.  Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  E. Van Cutsem,et al.  Tumor response to pre-operative chemotherapy (CT) with FOLFOX-4 for resectable colorectal cancer liver metastases (LM). Interim results of EORTC Intergroup randomized phase III study 40983. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Sargent,et al.  End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? , 2006, The oncologist.

[14]  T. Pawlik,et al.  Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Seufferlein,et al.  Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  K. Syrigos,et al.  FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) , 2006, British Journal of Cancer.

[17]  C. Tournigand,et al.  OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Nordlinger,et al.  Influence of Preoperative Chemotherapy on the Risk of Major Hepatectomy for Colorectal Liver Metastases , 2006, Annals of surgery.

[19]  F. Giuliante,et al.  Liver Resection for Primarily Unresectable Colorectal Metastases Downsized by Chemotherapy , 2005, Journal of Gastrointestinal Surgery.

[20]  S. Ricci,et al.  Biweekly irinotecan, oxaliplatin, and infusional 5-FU/LV (FOLFOXIRI) versus FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC): Results of a randomized, phase III trial by the Gruppo Oncologico Nord Ovest (G.O.N.O.) , 2006 .

[21]  D. Bentrem,et al.  CASH (Chemotherapy-Associated Steatohepatitis) costs. , 2006, Annals of surgery.

[22]  O. Goletti,et al.  Treatment with 5-Fluorouracil/Folinic Acid, Oxaliplatin, and Irinotecan Enables Surgical Resection of Metastases in Patients With Initially Unresectable Metastatic Colorectal Cancer , 2006, Annals of Surgical Oncology.

[23]  D. Sargent,et al.  Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Ellis,et al.  Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Köhne,et al.  Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  C. Bokemeyer,et al.  Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Carrato,et al.  Resectability of liver metastases (LM) in patients with advanced colorectal cancer (ACRA) after treatment with the combination of oxaliplatin (OXA), irinotecan (IRI) and 5FU. Final results of a phase II study , 2005 .

[28]  W. Hawkins,et al.  Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. , 2005, Journal of the American College of Surgeons.

[29]  R. Stupp,et al.  Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Adson.  Resection of liver metastases—When is it worthwhile? , 1987, World Journal of Surgery.

[32]  Y. Humblet,et al.  Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II study , 2005 .

[33]  P. Rougier,et al.  Cetuximab in combination with irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFIRI) in the first-line treatment of metastatic colorectal cancer (mCRC) , 2005 .

[34]  Mark Levine,et al.  Radiation therapy and tamoxifen: concurrent or sequential? That is the question. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  T. Mok,et al.  Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases , 2005, Medical oncology.

[36]  F. Lévi,et al.  Tumor Progression While on Chemotherapy: A Contraindication to Liver Resection for Multiple Colorectal Metastases? , 2004, Annals of surgery.

[37]  Bernard Paule,et al.  Rescue Surgery for Unresectable Colorectal Liver Metastases Downstaged by Chemotherapy: A Model to Predict Long-term Survival , 2004, Annals of surgery.

[38]  B. Siegel,et al.  Five-Year Survival After Resection of Hepatic Metastases From Colorectal Cancer in Patients Screened by Positron Emission Tomography With F-18 Fluorodeoxyglucose (FDG-PET) , 2004, Annals of surgery.

[39]  R. Advani,et al.  A phase II study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[41]  Kenneth Hess,et al.  Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases , 2004, Annals of surgery.

[42]  F. Giuliante,et al.  Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  J. Pignon,et al.  Results of R0 Resection for Colorectal Liver Metastases Associated With Extrahepatic Disease , 2004, Annals of Surgical Oncology.

[44]  L. Rubbia‐Brandt,et al.  Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  B. Nordlinger,et al.  Radiofrequency ablation in liver tumours. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Richard Stang,et al.  Resection of colorectal liver metastases , 1997, Journal of Gastrointestinal Surgery.

[48]  R. Adam,et al.  Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  W. Jarnagin,et al.  Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases , 2003, Journal of Gastrointestinal Surgery.

[50]  U. Baum,et al.  Impact of surgery on survival in palliative patients with metastatic colorectal cancer after first line treatment with weekly 24-hour infusion of high-dose 5-fluorouracil and folinic acid. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  J. Figueras,et al.  Resection rate and effect of postoperative chemotherapy on survival after surgery for colorectal liver metastases , 2001, The British journal of surgery.

[52]  T. Grube,et al.  [Resection of colorectal liver metastases. What prognostic factors determine patient selection?]. , 2001, Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen.

[53]  F. Lévi,et al.  Five-Year Survival Following Hepatic Resection After Neoadjuvant Therapy for Nonresectable Colorectal [Liver] Metastases , 2001, Annals of Surgical Oncology.

[54]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[55]  C. Wilson,et al.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. James,et al.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.

[57]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  F. Lévi,et al.  Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  B. Nordlinger,et al.  Long‐term survival following resection of colorectal hepatic metastases , 1997, The British journal of surgery.

[60]  W. Enker,et al.  Liver resection for colorectal metastases. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  F. Lévi,et al.  Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. , 1996, Annals of surgery.

[62]  B. Nordlinger,et al.  Surgical resection of colorectal carcinoma metastases to the liver: A prognostic scoring system to improve case selection, based on 1568 patients , 1996, Cancer.

[63]  A. Altendorf-Hofmann,et al.  Factors influencing the natural history of colorectal liver metastases , 1994, The Lancet.

[64]  Peter Schlag,et al.  Resection of the liver for colorectal carcinoma metastases , 1988, Diseases of the colon and rectum.